Function and regulation of the complement system in cardiovascular diseases

Frontiers in Bioscience

Volumn 12, Issue 12, 2007, Pages 4696-4708

  Oksjoki, Riina ^a   Kovanen, Petri T ^a   Meri, Seppo ^b   Pentikainen, Markku O ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Aneurysm; Atherosclerosis; Complement; Heart failure; Ischemia reperfusion injury; Myocardial infarction

Indexed keywords

ANIMALIA;

COMPLEMENT;

CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS;

EID: 34347215846     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2419     Document Type: Review

References (108)

1. th Edition. Elsevier Saunders, Philadelphia, Pennsylvania. (2005)
2. Helmy KY, Katschke KJ, Jr., Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren CM: CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927 (2006) (Pubitemid 43344233)
3. Bhakdi S, Fassbender W, Hugo F, Carreno MP, Berstecher C, Malasit P, Kazatchkine MD: Relative inefficiency of terminal complement activation. J Immunol 141, 3117-3122 (1988)
4. Isaak A, Prechl J, Gergely J, Erdei A: The role of CR2 in autoimmunity. Autoimmunity 39, 357-366 (2006) (Pubitemid 44269613)
5. Kaplan AP, Ghebrehiwet B, Silverberg M, Sealey JE: The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships. Crit Rev Immunol 3, 75-93 (1981)
6. Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 261, 12022-12027 (1986) (Pubitemid 17202758)
7. Hoffmann H, Siebeck M, Thetter O, Fink E, Philapitsch A: Effect of aprotinin and C1-esterase inhibitor on activation of the plasma kallikrein-kinin system in vivo. Prog Clin Biol Res 236 A, 159-164 (1987)
8. Vlaicu R, Rus HG, Niculescu F, Cristea A: Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55, 35-50 (1985) (Pubitemid 15064937)
9. Seifert PS, Hansson GK: Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 9, 802-811 (1989) (Pubitemid 20002211)
10. Vlaicu R, Rus HG, Niculescu F, Cristea A: Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall. Med Interne 23, 29-35 (1985) (Pubitemid 15027654)
11. Vlaicu R, Niculescu F, Rus HG, Cristea A: Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57, 163-177 (1985) (Pubitemid 16235906)
12. Seifert PS, Hugo F, Hansson GK, Bhakdi S: Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 60, 747-754 (1989) (Pubitemid 19168984)
13. Bhakdi S, Torzewski M, Klouche M, Hemmes M: Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19, 2348-2354 (1999) (Pubitemid 29477835)
14. Chang MK, Binder CJ, Torzewski M, Witztum JL: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99, 13043-13048 (2002)
15. Gershov D, Kim S, Brot N, Elkon KB: C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192, 1353-1364 (2000)
16. Oksjoki R, Kovanen PT, Pentikäinen MO: Role of complement activation in atherosclerosis. Curr Opin Lipidol 14, 477-482 (2003) (Pubitemid 37297302)
17. Oksjoki R, Jarva H, Kovanen PT, Laine P, Meri S, Pentikäinen MO: Association between complement factor h and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 23, 630-636 (2003) (Pubitemid 36438076)
18. Oksjoki R, Kovanen PT, Mäyränpää MI, Laine P, Blom AM, Meri S, Pentikäinen MO: Complement regulation in human atherosclerotic coronary lesions Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis 192, 40-48 (2007) (Pubitemid 46602305)
19. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S: Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 18, 369-378 (1998) (Pubitemid 28125631)
20. Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, Asuwa N, Choi-Miura NH, Tomita M: Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 18, 665-672 (1998) (Pubitemid 28177909)
21. Niculescu F, Rus HG, Vlaicu R: Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 65, 1-11 (1987) (Pubitemid 17065423)
22. Liszewski MK, Post TW, Atkinson JP: Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9, 431-455 (1991)
23. Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65, 532-537 (1991)
24. Seifert PS, Roth I, Schmiedt W, Oelert H, Okada N, Okada H, Bhakdi S: CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 96, 135-145 (1992)
25. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ: Human protectin (CD59), an 18, 000-20, 000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1-9 (1990) (Pubitemid 20296064)
26. Seifert PS, Hansson GK: Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest 84, 597-604 (1989) (Pubitemid 19196993)
27. Davitz MA, Low MG, Nussenzweig V: Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med 163, 1150-1161 (1986) (Pubitemid 16000414)
28. Saito E, Fujioka T, Kanno H, Hata E, Ueno T, Matsumoto T, Takahashi Y, Tochihara T, Yasugi T: Complement receptors in atherosclerotic lesions. Artery 19, 47-62 (1992)
29. Torzewski M, Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C, Hombach V, Gabbert HE: Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17, 2448-2452 (1997) (Pubitemid 28015980)
30. Niculescu F, Badea T, Rus H: Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 142, 47-56 (1999) (Pubitemid 28551809)
31. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D: Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 16, 673-677 (1996) (Pubitemid 26153112)
32. Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J: The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. FASEB J 14, 2370-2372 (2000)
33. Rus HG, Niculescu F, Vlaicu R: Co-localization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls. Immunol Lett 19, 27-32 (1988)
34. Geertinger P, Sorensen H: On the reduced atherogenic effects of cholesterol feeding on rabbits with congenital complement (C6) deficiency. Artery 1, 177-184 (1977)
35. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oelert H, Metz J, Bhakdi S: Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18, 1790-1795 (1998) (Pubitemid 28521070)
36. Saito E, Mitsui E, Fujioka T, Hara Y, Tochihara T, Kato S, Ito T, Ueno T, Kanno H, Yasugi T, Miyazaki W: Effect of K-76 COONa, an anticomplementary agent, on experimental atherosclerosis in rabbits. J Drug Dev (suppl) 3, 147-154 (1990) (Pubitemid 20354865)
37. Thorbjornsdottir P, Kolka R, Gunnarsson E, Bambir SH, Thorgeirsson G, Kotwal GJ, Arason GJ: Vaccinia Virus Complement Control Protein Diminishes Formation of Atherosclerotic Lesions: Complement Is Centrally Involved in Atherosclerotic Disease. Ann N Y Acad Sci 1056, 1-15 (2005) (Pubitemid 43030963)
38. Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, Mundt S, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA: ApoE (-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 286, 164-170 (2001) (Pubitemid 32917664)
39. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH: Influence of C3 deficiency on atherosclerosis. Circulation 105, 3025-3031 (2002) (Pubitemid 34693837)
40. Persson L, Boren J, Robertson AK, Wallenius V, Hansson GK, Pekna M: Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/-low-density lipoprotein receptor-/-mice 1. Arterioscler Thromb Vasc Biol 24, 1062-1067 (2004) (Pubitemid 38737832)
41. Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, Boyle JJ, Haskard DO: Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 170, 416-426 (2007) (Pubitemid 47339218)
42. Jonsson G, Truedsson L, Sturfelt G, Oxelius VA, Braconier JH, Sjoholm AG: Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 84, 23-34 (2005) (Pubitemid 40130182)
43. Nityanand S, Truedsson L, Mustafa A, Bergmark C, Lefvert AK: Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease. J Clin Immunol 19, 406-413 (1999) (Pubitemid 30039108)
44. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, San Giovanni JP, Mane SM, Mayne ST, Bracken MB, et al: Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005) (Pubitemid 40530070)
45. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, et al: Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419-421 (2005) (Pubitemid 40530081)
46. Edwards AO, Ritter R, III, Abel KJ, Manning A, Panhuysen C, Farrer LA: Complement factor H polymorphism and age-related macular degeneration. Science 308, 421-424 (2005) (Pubitemid 40530082)
47. Zee RY, Diehl KA, Ridker PM: Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case-control study. Atherosclerosis 187, 332-335 (2005) (Pubitemid 43963014)
48. Goverdhan SV, Lotery AJ, Cree AJ, Ye S: Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis. Atherosclerosis 188, 213-214 (2006) (Pubitemid 44142549)
49. Kardys I, Klaver CC, Despriet DD, Bergen AA, Uitterlinden AG, Hofman A, Oostra BA, van Duijn CM, de Jong PT, Witteman JC: A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study. J Am Coll Cardiol 47, 1568-1575 (2006) (Pubitemid 44313826)
50. Laine P, Pentikäinen MO, Wurzner R, Penttilä A, Paavonen T, Meri S, Kovanen PT: Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 90, 404-408 (2002)
51. Kostner KM, Fahti RB, Case C, Hobson P, Tate J, Marwick TH: Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta 365, 129-134 (2005)
52. Hoffmeister HM, Ehlers R, Buttcher E, Kazmaier S, Szabo S, Beyer ME, Steinmetz A, Seipel L: Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol 89, 909-912 (2002) (Pubitemid 34310285)
53. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, Wagner O, Huber K, Minar E, Wojta J, Schillinger M: Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 26, 2294-2299 (2005) (Pubitemid 41541394)
54. Chyatte D, Bruno G, Desai S, Todor DR: Inflammation and intracranial aneurysms. Neurosurgery 45, 1137-1146 (1999)
55. Frösen J, Piippo A, Paetau A, Kangasniemi M, Niemelä M, Hernesniemi J, Jääskeläinen J: Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke 35, 2287-2293 (2004) (Pubitemid 39311251)
56. Bruno G, Todor R, Lewis I, Chyatte D: Vascular extracellular matrix remodeling in cerebral aneurysms. J Neurosurg 89, 431-440 (1998) (Pubitemid 28405258)
57. Tulamo R, Frösen J, Junnikkala S, Paetau A, Pitkäniemi J, Kangasniemi M, Niemelä M, Jääskeläinen J, Jokitalo E, Karatas A, Hernesniemi J, et al: Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery 59, 1069-1076 (2006) (Pubitemid 44852101)
58. Capella JF, Paik DC, Yin NX, Gervasoni JE, Tilson MD: Complement activation and subclassification of tissue immunoglobulin G in the abdominal aortic aneurysm. J Surg Res 65, 31-33 (1996) (Pubitemid 26339191)
59. Väkevä A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S: Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol 144, 1357-1368 (1994) (Pubitemid 24172098)
60. Mathey D, Schofer J, Schafer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S: Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 15, 418-423 (1994) (Pubitemid 24127392)
61. Nauta AJ, Daha MR, Tijsma O, van de WB, Tedesco F, Roos A: The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol 32, 783-792 (2002) (Pubitemid 34257556)
62. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA: C5ainduced expression of P-selectin in endothelial cells. J Clin Invest 94, 1147-1155 (1994) (Pubitemid 24286457)
63. Albrecht EA, Chinnaiyan AM, Varambally S, Kumar-Sinha C, Barrette TR, Sarma JV, Ward PA: C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 164, 849-859 (2004) (Pubitemid 38235467)
64. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 185, 1619-1627 (1997) (Pubitemid 27203258)
65. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS: Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 155, 1434-1441 (1995)
66. Goodman MG, Chenoweth DE, Weigle WO: Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med 156, 912-917 (1982) (Pubitemid 12026997)
67. Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD: Both C3a and C3a (desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 177, 1622-1628 (1998) (Pubitemid 28243588)
68. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA: A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 156, 3455-3460 (1996)
69. Guo RF, Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol 23, 821-852 (2005) (Pubitemid 40563186)
70. Balzo del UH, Levi R, Polley MJ: Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Natl Acad Sci U S A 82, 886-890 (1985) (Pubitemid 15142782)
71. Balzo del U, Sakuma I, Levi R: Cardiac dysfunction caused by recombinant human C5A anaphylatoxin: mediation by histamine, adenosine and cyclooxygenase arachidonate metabolites. J Pharmacol Exp Ther 253, 171-179 (1990) (Pubitemid 20141495)
72. Schafer H, Mathey D, Hugo F, Bhakdi S: Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 137, 1945-1949 (1986) (Pubitemid 16021109)
73. Väkevä A, Laurila P, Meri S: Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol 143, 65-75 (1993) (Pubitemid 24058161)
74. Ito W, Schafer HJ, Bhakdi S, Klask R, Hansen S, Schaarschmidt S, Schofer J, Hugo F, Hamdoch T, Mathey D: Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res 32, 294-305 (1996) (Pubitemid 26246875)
75. Collard CD, Väkevä A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL: Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 156, 1549-1556 (2000) (Pubitemid 30646694)
76. Jordan JE, Montalto MC, Stahl GL: Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104, 1413-1418 (2001) (Pubitemid 32880155)
77. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, Stahl GL: Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 175, 541-546 (2005) (Pubitemid 40884360)
78. Zhang M, Takahashi K, Alicot EM, Vorup-Jensen T, Kessler B, Thiel S, Jensenius JC, Ezekowitz RA, Moore FD, Carroll MC: Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol 177, 4727-4734 (2006) (Pubitemid 44469806)
79. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H: Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162, 449-455 (2003) (Pubitemid 36267852)
80. Nijmeijer R, Lagrand WK, Lubbers YT, Visser CA, Meijer CJ, Niessen HW, Hack CE: C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 163, 269-275 (2003) (Pubitemid 36759611)
81. Krijnen PA, Ciurana C, Cramer T, Hazes T, Meijer CJ, Visser CA, Niessen HW, Hack CE: IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol 58, 382-388 (2005) (Pubitemid 40516169)
82. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, et al: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440, 1217-1221 (2006)
83. Väkevä A, Laurila P, Meri S: Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest 67, 608-616 (1992)
84. Väkevä A, Meri S: Complement activation and regulator expression after anoxic injury of human endothelial cells. APMIS 106, 1149-1156 (1998) (Pubitemid 29075899)
85. Turnberg D, Botto M, Lewis M, Zhou W, Sacks SH, Morgan BP, Walport MJ, Cook HT: CD59a deficiency exacerbates ischemia-reperfusion injury in mice. Am J Pathol 165, 825-832 (2004) (Pubitemid 39129290)
86. Zwaan de C., Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT: Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 23, 1670-1677 (2002) (Pubitemid 36287778)
87. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW: Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108, 1176-1183 (2003) (Pubitemid 37099984)
88. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108, 1184-1190 (2003) (Pubitemid 37099985)
89. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D, Jr., O'Neill WW, Todaro TG, Vahanian A, Van de WF: Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297, 43-51 (2007) (Pubitemid 46041725)
90. Thielmann M, Marggraf G, Neuhauser M, Forkel J, Herold U, Kamler M, Massoudy P, Jakob H: Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg 30, 285-293 (2006) (Pubitemid 44051901)
91. Sawa Y, Shimazaki Y, Kadoba K, Masai T, Fukuda H, Ohata T, Taniguchi K, Matsuda H: Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg 111, 29-35 (1996) (Pubitemid 26035169)
92. Lazar HL, Bokesch PM, van LF, Fitzgerald C, Emmett C, Marsh HC, Jr., Ryan U: Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110, II274-II279 (2004) (Pubitemid 39263735)
93. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, et al: Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100, 2499-2506 (1999) (Pubitemid 30005113)
94. Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, et al: Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 77, 942-949 (2004) (Pubitemid 38271065)
95. Verrier ED, Shernan SK, Taylor KM, Van de WF, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, et al: Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291, 2319-2327 (2004) (Pubitemid 38656298)
96. th Annual American College of Cardiology Scientific Session; March 11-14, 2006, Atlanta, Ga. Abstract 411-412.
97. Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, Caulin-Glaser T, Daher E, Kosiborod M, Bell L, Setaro JF: Serum complement activation in congestive heart failure. Am Heart J 141, 684-690 (2001) (Pubitemid 32260739)
98. Zwaka TP, Manolov D, Ozdemir C, Marx N, Kaya Z, Kochs M, Hoher M, Hombach V, Torzewski J: Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes. Am J Pathol 161, 449-457 (2002) (Pubitemid 36142154)
99. Oliveira GH, Brann CN, Becker K, Thohan V, Koerner MM, Loebe M, Noon GP, Torre-Amione G: Dynamic expression of the membrane attack complex (MAC) of the complement system in failing human myocardium. Am J Cardiol 97, 1626-1629 (2006) (Pubitemid 43737016)
100. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F: Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99, 649-654 (1999) (Pubitemid 29077363)
101. Schultheiss HP. The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy-clinical and experimental data. Springer Semin Immunopathol 11, 15-30 (1989)
102. Wolff PG, Kuhl U, Schultheiss HP: Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J 117, 1303-1309 (1989) (Pubitemid 19150761)
103. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9, 1477-1483 (2003) (Pubitemid 38004774)
104. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR: Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2, 739-745 (2001) (Pubitemid 32747164)
105. Martino TA, Petric M, Brown M, Aitken K, Gauntt CJ, Richardson CD, Chow LH, Liu PP: Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244, 302-314 (1998) (Pubitemid 28384095)
106. Morgan BP, Harris CL: Complement therapeutics; history and current progress. Mol Immunol 40, 159-170 (2003) (Pubitemid 36959825)
107. Mulligan MS, Warner RL, Rittershaus CW, Thomas LJ, Ryan US, Foreman KE, Crouch LD, Till GO, Ward PA: Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol 162, 4952-4959 (1999) (Pubitemid 29314902)
108. Carroll M. Immunology: exposure of an executioner. Nature 444, 159-160 (2006) (Pubitemid 44722047)